In animal experiments, TGF-β neutralizing monoclonal antibodies and drugs such as pirfenidone effectively alleviated renal fibrosis by reducing the activity of the TGF-β1 gene promoter and the release of the TGF-β1 protein in DKD [63,64,65]. The gene discussed is TGFB1; the disease is diabetic kidney disease.